search
Back to results

Pitocin or Oral Misoprostol for PROM IOL (POM PROM)

Primary Purpose

PROM

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Misoprostol
Oxytocin
Sponsored by
University of Pennsylvania
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for PROM

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • English Speaking
  • PROM </= 24 hours with no evidence of labor
  • >/= 36 weeks gestation
  • Agreeable to induction of labor
  • Nulliparous
  • Singleton pregnancy
  • Vertex presentation
  • Cervical dilation </=2 cm AND Bishop score < 8

Exclusion Criteria:

  • Prior cesarean section
  • Other contraindication to vaginal delivery
  • Intrauterine Fetal Demise
  • Major Congenital Anomaly
  • Intraamniotic infection diagnosed at time of admission
  • 36 weeks - 36 weeks and 6 days with unknown GBS status

Sites / Locations

  • Hospital of the University of Pennsylvania

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Oral Misoprostol

Oxytocin

Arm Description

Oral misoprostol 50 mcg q4H for up to 6 doses or until cervical ripening is no longer indicated

IV Oxytocin 2mU/min, increased by 2mU/min q15 minutes per hospital protocol

Outcomes

Primary Outcome Measures

Time from IOL to delivery
Time (hours) from start of IOL to delivery

Secondary Outcome Measures

Infection
Suspected intraamniotic infection
Time from PROM to delivery
Time (hours) from PROM to delivery
Time from IOL to vaginal delivery
Time (hours) from PROM to delivery
Time from PROM to vaginal delivery
Time (hours) from PROM to vaginal delivery
Cesarean delivery
Cesarean section rate
Maternal morbidity
Composite maternal morbidity: postpartum hemorrhage, blood transfusion, endometritis, wound infection, VTE, hysterectomy, ICU admission, readmission within 1 week, death
Neonatal Morbidity
Composite neonatal morbidity: Neonatal intensive care (ICN) admission > 48 hours, neonatal blood transfusion, hypoxic ischemic encephalopathy, intraventricular hemorrhage grade III or IV, headcooling, severe respiratory distress syndrome, necrotizing enterocolitis, sepsis, death

Full Information

First Posted
July 19, 2019
Last Updated
July 26, 2023
Sponsor
University of Pennsylvania
search

1. Study Identification

Unique Protocol Identification Number
NCT04028765
Brief Title
Pitocin or Oral Misoprostol for PROM IOL
Acronym
POM PROM
Official Title
POM PROM: Pitocin or Oral Misoprostol for PROM IOL in Nulliparous Women With Unfavorable Cervical Exams
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
August 12, 2019 (Actual)
Primary Completion Date
December 8, 2022 (Actual)
Study Completion Date
January 8, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Pennsylvania

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Premature rupture of membranes (PROM) is a common occurrence of pregnancies at term. A delay from PROM to labor is associated with an increased risk of intrauterine infection and associated maternal and fetal morbidity; therefore, induction of labor (IOL) is recommended. The ideal agent for IOL is not known, particularly among specific subpopulations. The primary aim of this study is to determine if oxytocin (Pitocin) or oral misoprostol results in a shorter interval to delivery after the start of induction among nulliparous women with unfavorable cervical exams with term PROM.
Detailed Description
Premature rupture of membranes (PROM) occurs in approximately 8% of pregnancies at term.1 Although onset of spontaneous labor is often prompt after membrane rupture, a delay from PROM to labor is associated with an increased risk of intrauterine infection and its associated maternal and fetal complications. For this reason, ACOG endorses induction of labor for PROM "if spontaneous labor does not occur near the time of presentation." The optimal method for PROM induction is less clear. Prior literature has examined the use of Pitocin (Oxytocin), vaginal and oral misoprostol, and dinoprost with mixed results. The TermPROM study found an increased risk of chorioamnionitis and NICU admission among women treated with vaginal misoprostol for induction. The postulated link between vaginal misoprostol and chorioamnionitis is the need for vaginal examination for placement of the misoprostol; more vaginal examinations could potentially increase the risk for infection. Utilizing oral misoprostol would eliminate the need for a vaginal exam for administration, thereby potentially mitigating this risk of infection. Currently, vaginal and oral misoprostol as well as oxytocin are used routinely in clinical care based on provider discretion. Among 7 randomized controlled trials examining the use of oral misoprostol as compared to oxytocin, two found oral misoprostol to result in faster induction to delivery, two found oxytocin to result in faster deliveries, and the remaining three found no difference between the two.3-9 These studies are limited by small sample size, inadequate reporting of patient demographics, varied misoprostol and oxytocin protocols, and inconsistent primary outcomes. Therefore, the utility of oral misoprostol in this population has not been established. Furthermore, its efficacy in specific patient populations is unreported in the literature. The primary aim of this study is to determine if oxytocin or oral misoprostol results in a shorter interval to delivery after the start of induction among nulliparous women with unfavorable cervical exams with PROM.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
PROM

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
108 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Oral Misoprostol
Arm Type
Active Comparator
Arm Description
Oral misoprostol 50 mcg q4H for up to 6 doses or until cervical ripening is no longer indicated
Arm Title
Oxytocin
Arm Type
Active Comparator
Arm Description
IV Oxytocin 2mU/min, increased by 2mU/min q15 minutes per hospital protocol
Intervention Type
Drug
Intervention Name(s)
Misoprostol
Intervention Description
As above
Intervention Type
Drug
Intervention Name(s)
Oxytocin
Intervention Description
As above
Primary Outcome Measure Information:
Title
Time from IOL to delivery
Description
Time (hours) from start of IOL to delivery
Time Frame
Enrollment to Delivery
Secondary Outcome Measure Information:
Title
Infection
Description
Suspected intraamniotic infection
Time Frame
Enrollment to Delivery
Title
Time from PROM to delivery
Description
Time (hours) from PROM to delivery
Time Frame
Enrollment to Delivery
Title
Time from IOL to vaginal delivery
Description
Time (hours) from PROM to delivery
Time Frame
Enrollment to Delivery
Title
Time from PROM to vaginal delivery
Description
Time (hours) from PROM to vaginal delivery
Time Frame
Enrollment to Delivery
Title
Cesarean delivery
Description
Cesarean section rate
Time Frame
Enrollment to Delivery
Title
Maternal morbidity
Description
Composite maternal morbidity: postpartum hemorrhage, blood transfusion, endometritis, wound infection, VTE, hysterectomy, ICU admission, readmission within 1 week, death
Time Frame
Enrollment to 1 week postpartum
Title
Neonatal Morbidity
Description
Composite neonatal morbidity: Neonatal intensive care (ICN) admission > 48 hours, neonatal blood transfusion, hypoxic ischemic encephalopathy, intraventricular hemorrhage grade III or IV, headcooling, severe respiratory distress syndrome, necrotizing enterocolitis, sepsis, death
Time Frame
Enrollment to 1 week postpartum

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: English Speaking PROM </= 24 hours with no evidence of labor >/= 36 weeks gestation Agreeable to induction of labor Nulliparous Singleton pregnancy Vertex presentation Cervical dilation </=2 cm AND Bishop score < 8 Exclusion Criteria: Prior cesarean section Other contraindication to vaginal delivery Intrauterine Fetal Demise Major Congenital Anomaly Intraamniotic infection diagnosed at time of admission 36 weeks - 36 weeks and 6 days with unknown GBS status
Facility Information:
Facility Name
Hospital of the University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29266075
Citation
Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 188: Prelabor Rupture of Membranes. Obstet Gynecol. 2018 Jan;131(1):e1-e14. doi: 10.1097/AOG.0000000000002455.
Results Reference
background
PubMed Identifier
8598837
Citation
Hannah ME, Ohlsson A, Farine D, Hewson SA, Hodnett ED, Myhr TL, Wang EE, Weston JA, Willan AR. Induction of labor compared with expectant management for prelabor rupture of the membranes at term. TERMPROM Study Group. N Engl J Med. 1996 Apr 18;334(16):1005-10. doi: 10.1056/NEJM199604183341601.
Results Reference
background
PubMed Identifier
12834947
Citation
Al-Hussaini TK, Abdel-Aal SA, Youssef MA. Oral misoprostol vs. intravenous oxytocin for labor induction in women with prelabor rupture of membranes at term. Int J Gynaecol Obstet. 2003 Jul;82(1):73-5. doi: 10.1016/s0020-7292(03)00136-x. No abstract available.
Results Reference
background
PubMed Identifier
14526301
Citation
Crane JM, Delaney T, Hutchens D. Oral misoprostol for premature rupture of membranes at term. Am J Obstet Gynecol. 2003 Sep;189(3):720-4. doi: 10.1067/s0002-9378(03)00768-3.
Results Reference
background
PubMed Identifier
10576189
Citation
Butt KD, Bennett KA, Crane JM, Hutchens D, Young DC. Randomized comparison of oral misoprostol and oxytocin for labor induction in term prelabor membrane rupture. Obstet Gynecol. 1999 Dec;94(6):994-9. doi: 10.1016/s0029-7844(99)00423-8.
Results Reference
background
PubMed Identifier
10688506
Citation
Ngai SW, Chan YM, Lam SW, Lao TT. Labour characteristics and uterine activity: misoprostol compared with oxytocin in women at term with prelabour rupture of the membranes. BJOG. 2000 Feb;107(2):222-7. doi: 10.1111/j.1471-0528.2000.tb11693.x.
Results Reference
background
PubMed Identifier
14586349
Citation
Mozurkewich E, Horrocks J, Daley S, Von Oeyen P, Halvorson M, Johnson M, Zaretsky M, Tehranifar M, Bayer-Zwirello L, Robichaux A 3rd, Droste S, Turner G; MisoPROM study. The MisoPROM study: a multicenter randomized comparison of oral misoprostol and oxytocin for premature rupture of membranes at term. Am J Obstet Gynecol. 2003 Oct;189(4):1026-30. doi: 10.1067/s0002-9378(03)00845-7.
Results Reference
background
PubMed Identifier
26866082
Citation
Mbaluka CM, Kamau K, Karanja JG, Mugo N. EFFECTIVENESS AND SAFETY OF 2-HOURLY 20 MCG ORAL MISOPROSTOL SOLUTION COMPARED TO STANDARD INTRAVENOUS OXYTOCIN IN LABOUR INDUCTION DUE TO PRE-LABOUR RUPTURE OF MEMBRANES AT TERM: A RANDOMISED CLINICAL TRIAL AT KENYATTA NATIONAL HOSPITAL. East Afr Med J. 2014 Sep;91(9):303-10.
Results Reference
background

Learn more about this trial

Pitocin or Oral Misoprostol for PROM IOL

We'll reach out to this number within 24 hrs